ArticleCureus2026
Giant Left Atrial Myxoma Causing Functional Mitral Stenosis: A Minimally Invasive Approach.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac myxoma is the most common primary cardiac tumor and typically arises in the left atrium. Large, mobile myxomas may prolapse through the mitral valve and produce functional mitral stenosis with secondary pulmonary hypertension. We report a 57-year-old woman with cardiovascular risk factors (hypercholesterolemia and obesity) who presented with New York Heart Association class III dyspnea and palpitations. First-line transthoracic echocardiography revealed a giant, mobile left atrial mass (4.7 x 4.8 cm) attached to the basal third of the interatrial septum, prolapsing into the left ventricle and producing a mean transmitral gradient of 16 mmHg with severe pulmonary hypertension (estimated pulmonary artery systolic pressure approximately 80 mmHg). Preoperative coronary computed tomography (CT) angiography, performed to exclude significant coronary artery disease given her cardiovascular risk factors and to characterize the intracardiac mass non-invasively, confirmed the mass and showed coronary atheromatosis without significant stenosis. The mass was surgically resected within two weeks of diagnosis via a minimally invasive thoracoscopic approach, decided in a multidisciplinary heart team meeting, with femoro-femoral cannulation, without preoperative anticoagulation; activity restriction and close clinical monitoring were maintained while awaiting surgery. The postoperative course was uncomplicated, with early extubation and rapid mobilization. At one-month follow-up, the transmitral gradient and pulmonary artery pressures had normalized, with a stable, mild residual mitral regurgitation and complete symptom resolution. Histopathological examination showed a well-circumscribed, non-encapsulated, smooth-surfaced proliferation of spindle-to-stellate cells within an abundant myxoid stroma, without atypia, mitoses, or necrosis; immunohistochemistry was positive for calretinin, confirming the diagnosis of myxoma. This case illustrates the diagnostic and hemodynamic impact of a giant left atrial myxoma and the feasibility of a minimally invasive thoracoscopic resection in a carefully selected patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.